Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Cho

Showing results (921-930 of 922) with videos related to

Pageof 93
Sort By:
You have reached the last page of results.This site can display upto 922 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2024
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAE Felip, B C Cho, V Gutiérrez, et al.
The New England Journal of Medicine|June 26, 2024
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i>-Mutated Advanced NSCLCByoung C Cho, Shun Lu, Enriqueta Felip, et al.
Pageof 93

Showing results (921-930 of 922) with videos related to

Sort By:
Pageof 93
You have reached the last page of results.This site can display upto 922 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2024
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAE Felip, B C Cho, V Gutiérrez, et al.
The New England Journal of Medicine|June 26, 2024
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i>-Mutated Advanced NSCLCByoung C Cho, Shun Lu, Enriqueta Felip, et al.
Pageof 93